AI Proteins to aim miniproteins at BMS targets

Boston, USA-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb (NYSE: BMY).

As part of the collaboration, AI Proteins will use its AI-driven platform to design and optimize miniproteins against targets of interest to BMS. 

These de novo designed miniproteins, characterized by their small size and high affinity, have the potential to offer significant advantages over traditional antibody-based therapies, including improved tissue penetration and rapid clearance.